Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 649-655

  Breitling, L P ^a   Grandi, N C ^a   Hahmann, H ^b   Wusten B ^c   Rothenbacher, D ^a   Brenner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Klinik Schwabenland   (Germany)

^c Klinik Am Südpark   (Germany)

Author keywords

Coronary heart diseases; Gamma glutamyltransferase; Prognosis; Prospective cohort study; Secondary cardiovascular disease

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GERMANY; HAZARD RATIO; HOSPITAL PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REHABILITATION CARE; REHABILITATION CENTER;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; TIME FACTORS;

EID: 77953229244     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.037     Document Type: Article

References (31)

1. Lee D.H., Silventoinen K., Hu G., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006, 27(18):2170-2176.
2. Meisinger C., Doring A., Schneider A., Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006, 189(2):297-302.
3. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112(14):2130-2137.
4. Strasak A.M., Kelleher C.C., Klenk J., et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality. A prospective population-based study in 76 113 Austrian adults. Arterioscler Thromb Vasc Biol 2008, 28(10):1857-1865.
5. Wannamethee G., Ebrahim S., Shaper A.G. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995, 142(7):699-708.
6. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201(1):168-175.
7. Meisinger C., Lowel H., Heier M., Schneider A., Thorand B. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005, 258(6):527-535.
8. Nakanishi N., Suzuki K., Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004, 27(6):1427-1432.
9. Peer A., Falkensammer G., Alber H., et al. Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart 2009, 95(4):297-303.
10. Karlson B.W., Wiklund O., Hallgren P., Sjolin M., Lindqvist J., Herlitz J. Ten-year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia. J Intern Med 2000, 247(4):449-456.
11. Emdin M., Passino C., Michelassi C., et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001, 22(19):1802-1807.
12. Poelzl G., Eberl C., Achrainer H., et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009, 2(4):294-302.
13. Koenig W., Twardella D., Brenner H., Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006, 26(7):1586-1593.
14. Rothenbacher D., Koenig W., Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006, 166(22):2455-2460.
15. Statistical analysis software, release 9.2 [program] 2008, SAS Institute, Cary, NC.
16. Hosmer D.W., Lemeshow S. Applied survival analysis: regression modeling of time to event data 1999, Wiley, New York, Chichester.
17. Burger M., Ziese T. Bundes-Gesundheitssurvey: Alkohol-Konsumverhalten in Deutschland 2003, Robert Koch-Institut, Berlin.
18. Breitling L.P., Raum E., Muller H., Rothenbacher D., Brenner H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 2009, 49(3):802-808.
19. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112(14):2078-2080.
20. Franzini M., Corti A., Martinelli B., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques-biochemical similarities with the circulating enzyme. Atherosclerosis 2009, 202(1):119-127.
21. Lee D.H., Blomhoff R., Jacobs D.R. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 2004, 38(6):535-539.
22. Lee D.H., Jacobs D.R. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005, 178(2):327-330.
23. Emdin M., Passino C., Michelassi C., Donato L., Pompella A., Paolicchi A. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 2009, 136(1):80-85.
24. Royston P., Altman D.G., Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25(1):127-141.
25. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27(12):2729-2735.
26. Sawe U., Erhardt L.R., Sjogren A. Pattern of enzyme activity following acute myocardial infarction with special reference to gamma-glutamyl transpeptidase. Acta Med Scand 1976, 199(3):217-221.
27. Krupicka J., Janota T., Kasalova Z., Hradec J. Natriuretic peptides-physiology, pathophysiology and clinical use in heart failure. Physiol Res 2009, 58(2):171-177.
28. Hozawa A., Okamura T., Kadowaki T., et al. Gamma-glutamyltransferase predicts cardiovascular death among Japanese women. Atherosclerosis 2007, 194(2):498-504.
29. Sabatine M.S., Morrow D.A., Jablonski K.A., et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115(12):1528-1536.
30. Sinning J.M., Bickel C., Messow C.M., et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006, 27(24):2962-2968.
31. O'Donoghue M., Morrow D.A. The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol 2008, 23(4):309-314.